X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

World Cell & Gene Therapy Supply Chain To Hit $3.12b By 2031

Content Team by Content Team
8th April 2023
in Facilities & Operation, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The global cell and gene therapy (CGT) supply chain and logistics industry is predicted to reach $3.12 billion by 2031, based on a market report.

This equates to a very promising compound annual growth rate (CAGR) of 11.2% between 2023 and 2031. The growing demand for cell and gene therapies, increased medical trials, and advances in real-time supply chain operations are expected to improve the quality of cell and gene therapy supply chain management services throughout the forecast period.

More customizable facilities, improved efficacy of CGT supply chain services, and advancements in supply services that are innovative, for instance, are projected to boost market expansion, according to the report.

Furthermore, an issue anticipated to trouble the market growth across the projected period happens to be the steep funding cost that is required for CGT supply chain services, as well as a lack of benchmark therapy protocols. Other barriers in this market happen to be the provision when it comes to personalised treatments as well as smart packaging, according to the research.

In January 2023, a contract research organization (CRO) and a supply chain solutions provider established a new strategic collaboration. The agreement will be the company’s first completely integrated biopharmaceutical and supply chain solution. It will assist in accelerating treatment and enhancing outcomes by increasing access to these therapies.

According to the report, prominent manufacturers are concentrating on providing clients with customizable services. Partnerships, mergers, and acquisitions, and collaborations within the area are also assisting in business growth.

According to the report, North America is the leading revenue holder in the market. Increased government spending on cell therapy R&D to treat various diseases, as well as a high demand for novel medicines, are both drivers.

In line with the report, North America, followed by Europe, has the largest market share because of increased CGT supply chain service efficiency and rapid adoption of modern technologies.

The Asia-Pacific market is also predicted to grow quicker. It is attributable to growing cell therapy manufacturing verticals and the improved efficiency of CGT supply chain services.

Previous Post

Cell-Energy Activity In Organs, Tissues By New MRI Method

Next Post

Pharma Supply Chain Present Danger As Drug Shortages Rise

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Pharma Supply Chain Present Danger As Drug Shortages Rise

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In